Tidal Investments LLC Buys 48,885 Shares of Fresenius Medical Care AG & Co. KGaA $FMS

Key Points

• Tidal Investments nearly doubled its Fresenius Medical Care stake in the second quarter, adding 48,885 shares to own 99,790 shares valued at approximately $2.26 million.
• Other institutional investors also increased or initiated positions, but institutional ownership remains relatively low at 8.37% of the company’s stock.
• Analyst sentiment is cautious, with six Hold and five Sell ratings producing a consensus “Reduce” rating and an average price target of $23.57. Fresenius Medical Care nevertheless beat quarterly estimates, reporting $0.66 EPS and $5.55 billion in revenue.

Tidal Investments LLC grew its stake in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Free Report) by 96.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 99,790 shares of the company's stock after acquiring an additional 48,885 shares during the quarter. Tidal Investments LLC's holdings in Fresenius Medical Care AG & Co. KGaA were worth $2,256,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Integrated Wealth Concepts LLC bought a new position in Fresenius Medical Care AG & Co. KGaA during the second quarter valued at approximately $91,000. Allworth Financial LP grew its position in Fresenius Medical Care AG & Co. KGaA by 31.5% in the 2nd quarter. Allworth Financial LP now owns 3,552 shares of the company's stock worth $80,000 after purchasing an additional 850 shares during the period. Syon Capital LLC bought a new stake in Fresenius Medical Care AG & Co. KGaA in the 2nd quarter worth approximately $292,000. Baron Wealth Management LLC purchased a new stake in Fresenius Medical Care AG & Co. KGaA during the 2nd quarter valued at $336,000. Finally, GAMMA Investing LLC lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 170.9% during the 2nd quarter. GAMMA Investing LLC now owns 21,695 shares of the company's stock valued at $491,000 after buying an additional 13,687 shares during the period. 8.37% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

FMS has been the topic of a number of research reports. Zacks Research upgraded Fresenius Medical Care AG & Co. KGaA from a "strong sell" rating to a "hold" rating in a research note on Monday, July 6th. BNP Paribas Exane cut Fresenius Medical Care AG & Co. KGaA from a "neutral" rating to an "underperform" rating and set a $19.90 price objective for the company. in a research report on Tuesday, July 28th. Weiss Ratings reissued a "hold (c)" rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, August 4th. Citigroup restated a "neutral" rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Friday, July 17th. Finally, Truist Financial set a $25.00 price target on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Wednesday, August 5th. Six investment analysts have rated the stock with a Hold rating and five have assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Reduce" and an average target price of $23.57.

Fresenius Medical Care AG & Co. KGaA Price Performance

NYSE FMS opened at $22.95 on Thursday. The business's fifty day moving average is $23.73 and its 200 day moving average is $22.99. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $20.02 and a fifty-two week high of $27.64. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 1.07. The company has a market capitalization of $12.32 billion, a PE ratio of 11.89, a price-to-earnings-growth ratio of 4.26 and a beta of 0.76.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.62 by $0.04. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.28% and a net margin of 4.83%.The company had revenue of $5.55 billion during the quarter, compared to the consensus estimate of $5.48 billion. Sell-side analysts predict that Fresenius Medical Care AG & Co. KGaA will post 2.25 earnings per share for the current year.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on kidney disease and dialysis services. The company provides hemodialysis and peritoneal dialysis treatments through a global network of outpatient dialysis clinics and supports patients with related care and medical services.

In addition to operating dialysis centers, Fresenius Medical Care develops and manufactures products used in renal care. Its portfolio includes dialysis machines, dialyzers, bloodlines, concentrates, solutions, pharmaceuticals and other disposable supplies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.